The Difoprev® system in treatment of the skin of the elderly: preliminary data obtained in patients with dryness and hyperkeratosis

Leonardo Aluigi
Center and School of Echography, Department of Internal Medicine, Maggiore Hospital, Bologna, Italy

Background: Aging brings with it a number of structural and functional modifications of the skin and adnexa, particularly in the lower extremities, which may determine a gradual reduction in elasticity, with associated functional alterations which may determine preulcerative lesions. The aim of this study was to test the efficacy of the Difoprev® system, consisting in a sock functioning as a vehicle for microcapsules containing moisturizing agents (Pseudoalteromonas ferment extract, a glycoprotein synthesized by the bacterium, Pseudoalteromonas antarctica NF3). The system is already widely used for cutaneous treatment in cases of neuropathic diabetic foot, and in prevention/treatment of dryness and hyperkeratosis of the skin of the lower extremities in elderly persons (shin/foot).

Methodology: Sixteen patients aged >70 years (group A) were treated with the Difoprev® system for 8 weeks. This group was compared with 8 patients of the same age (group B) who wore the same type of sock without microcapsules. Following initial assessment at the time of recruitment, the patients underwent controls at 15, 30, and 60 days to assess the degree of hydration of the skin derived from an objective evaluation of degree of keratosis according to an arbitrary scale of seriousness ranging from 1 (absent) to 4 (marked). The changes were rated according to a scale ranging from 1 (no improvement) to 5 (marked improvement). A comparative study of all cases was conducted by means of photographs taken as the treatment commenced and on termination of treatment.

Results: Most patients treated with Difoprev® presented a reduction in the degree of keratosis of the skin (90%, of whom 15% had marked improvement), compared to the patients who wore only the sock with no microcapsules (10% with slight improvement). None of the patients undergoing Difoprev® system treatment displayed signs of intolerance or untoward reactions.

Conclusion: While the clinical assessment was conducted on a small number of patients, the results obtained nevertheless demonstrate that the Difoprev® system is a safe, simple method for obtaining improvements to the skin of elderly people by reduction of the degree of keratosis through enhanced hydration.

Keywords: nanotechnologies, cutaneous hydration, hyperkeratosis, ulcerative lesions

Background
As we age, also in the absence of clear venous, arterial, or neurological diseases, our skin will tend to become less elastic and will dry. It may also produce symptomatology of pruriginous conditions and of desquamation both spontaneous and induced by scratching.1-3 The resulting thinning of the epidermis brings with it a reduction of protective capacities, and exposes the skin to desquamation phenomena and, occasionally, to preulcerative lesions. Above all, in the shins and feet, the skin displays a gradual reduction in elasticity, with a reduction in the thickness of the matrix of the
Increased formation of Type-I and Type-IV collagen
• Increased formation of elastin
• Endowed with a significant “anti-wrinkling” effect
• Displays repair effect in vitro
• Prevents dryness of the skin and protects the epidermis from extreme cold.

**Figure 1** Properties of the *Pseudoalteromonas antarctica* NF3 glycoprotein.
**Notes:** (A) Appearance under electronic microscope of the glycoprotein synthesized by *Pseudoalteromonas antarctica* NF3. (B) List of the documented properties of the glycoprotein. Data from Muller et al; Sung and Jung; Nevot et al.

**Figure 2** Antiwrinkling effect of *Pseudoalteromonas antarctica* NF3 glycoprotein.
**Notes:** Antiwrinkling effect obtained following in vitro application of the *Pseudoalteromonas antarctica* NF3 glycoprotein for 30 days, demonstrated by confocal fluorescence microscopic examination that the depth of the wrinkle had clearly been reduced between (A) time 0 and (B) time of termination of the application.
for creams. The Difoprev® system is based on a technology derived from nanostructured lipid carriers, which has been demonstrated to be highly effective as a vehicle for both cosmetic and dermatological preparations. It consists of a sock made of a special synthetic fiber, polyamide fiber (Meryl® [Nylstar S.P.A Yarn Manufacturer - Italy, Cesano Maderno, Italy], which is smooth and does not irritate the skin, and which, because of negative/positive surface charges interaction, can be loaded with the microcapsules containing the active moisturizer. When the socks are worn, the contained microcapsules constantly release the agent to the patient for the whole time the sock is in contact with the skin. Each charge lasts for 36 hours. This eliminates the need to moisturize skin, while also maximizing the time of application of the active agent. The sock is recharged with the microcapsules at each washing. The moisturizing agent is an emulsion of liposomes, made up of a core of lipids (phosphatidylcholine) coated by the glycoprotein secreted by the bacterium Pseudoalteromonas antarctica. This protein, along with other proteins found in microorganisms, is able to coat liposomes, protecting them from surfactant agents, thus increasing their solubility and availability. The glycoprotein (Pseudoalteromonas ferment extract), which is synthesized by a bacterium (P. antarctica NF3), is endowed with properties particularly indicated for homeostatic maintenance of the skin and subcutaneous tissue (Figures 1 and 2).

The liposomes, positively charged, can exert a range of activities in the skin. They interact with the extracellular lipid junctions in the stratum corneum and isolate the deeper layer from the outer ones. It is also reported that the liposomes have a positive effect on fibroblast functions.

This system was designed initially as a means of prevention and treatment of cutaneous trophism, especially for patients with diabetic pathological conditions, vascular pathological conditions, or wounds or sequelae of amputation. In view of the product’s characteristics and demonstrated efficacy, the indications were then broadened to include also perilesional skin treatment and treatment of skin lesions induced by bandages or elastic compression. The aim of this work is to assess the efficacy of this system in the treatment of the skin of elderly patients.

### Materials and methods

Over a period of 8 weeks, a consecutive series of 16 male and female outpatients (age >70 years) underwent treatment with the Difoprev® system (consisting in microcapsules containing a glycoprotein synthesized by the bacterium, P. antarctica NF3, which are anchored to the threads of a very comfortable sock made of a special polyamide synthetic fiber, Meryl®). A comparison was conducted with 8 patients of the same age bracket who wore the same type of sock, but without the microfilm. The patients were assigned to one of the two treatment groups on the basis of a randomization list: group A, managed with the full system and group B, managed with socks with no active principle. The duration of the effect of application is approximately 36 hours. During this period, the glycoprotein contained in the microcapsule, released following rupture of the microcapsules during walking, exerts its moisturizing action as it spreads within the skin; the peculiarity of the system consists in the possibility of “recharging” the sock after washing by dipping it in a solution containing microcapsules. The solution was provided as part of the system. The patients

<table>
<thead>
<tr>
<th>Keratosis</th>
<th>Degree</th>
</tr>
</thead>
<tbody>
<tr>
<td>Absent</td>
<td>1</td>
</tr>
<tr>
<td>Barely visible keratosis</td>
<td>2</td>
</tr>
<tr>
<td>Clearly visible keratosis</td>
<td>3</td>
</tr>
<tr>
<td>Serious keratosis</td>
<td>4</td>
</tr>
</tbody>
</table>

### Table 1. Scale of the degree of keratosis

**Figure 3.** Clinical appearance of skin.

**Notes:** Clinical appearance of the skin with, in ascending order, degrees of keratosis corresponding to those given in Table 1. (1) Absent; (2) barely visible keratosis; (3) clearly visible keratosis; and (4) serious keratosis.
were duly provided with instructions concerning use of the system, with attention paid in particular to the charging procedure. Of course, during the study periods no creams or ointments were used, and use of a neutral soap was recommended for personal hygiene. The patients displayed no symptomatology indicative of vascular, arterial, venous, or neurological diseases. Regardless, all patients underwent preliminary instrumental instrumental echo

### Table 2 Scale of degree of improvement obtained through use of the Difoprev® system

<table>
<thead>
<tr>
<th>No variation</th>
<th>1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Slight improvement</td>
<td>2</td>
</tr>
<tr>
<td>Moderate improvement</td>
<td>3</td>
</tr>
<tr>
<td>Improvement</td>
<td>4</td>
</tr>
<tr>
<td>Marked improvement</td>
<td>5</td>
</tr>
</tbody>
</table>

Note: Difoprev® system; LVM Technologies, Bologna, Italy.

### Table 3 Degree of keratosis noted on the first examination and after 15, 30, and 60 days

<table>
<thead>
<tr>
<th>Keratosis</th>
<th>Examination</th>
<th>I</th>
<th>II</th>
<th>III</th>
<th>IV</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group A</td>
<td>Days</td>
<td>0</td>
<td>15</td>
<td>30</td>
<td>60</td>
</tr>
<tr>
<td>1</td>
<td>3.5</td>
<td>2</td>
<td>1.5</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>3</td>
<td>2.5</td>
<td>1.5</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>2.5</td>
<td>2</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>4</td>
<td>3.5</td>
<td>2</td>
<td>1.5</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>3</td>
<td>2.5</td>
<td>1.5</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>4</td>
<td>3.5</td>
<td>2</td>
<td>1.5</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>3.5</td>
<td>2</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>3</td>
<td>2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>4</td>
<td>3.5</td>
<td>2</td>
<td>1.5</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>4</td>
<td>3.5</td>
<td>2</td>
<td>1.5</td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>3.5</td>
<td>2</td>
<td>1.5</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>3.5</td>
<td>2</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>2.5</td>
<td>2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>3.5</td>
<td>3</td>
<td>1.5</td>
<td>1.5</td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>2.5</td>
<td>2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16</td>
<td>3</td>
<td>2.5</td>
<td>2</td>
<td>1.5</td>
<td></td>
</tr>
<tr>
<td>Average</td>
<td>3.31</td>
<td>2.59</td>
<td>1.53</td>
<td>1.21</td>
<td></td>
</tr>
<tr>
<td>St dev</td>
<td>0.54</td>
<td>0.61</td>
<td>0.46</td>
<td>0.31</td>
<td></td>
</tr>
</tbody>
</table>

ns ns P<0.01 ns

### Figure 4 Comparison of keratosis between the two patient groups.

Note: The graph indicates a clear reduction in the degree of keratosis in group A patients (blue line) compared to group B patients (purple line).
were also requested to keep all the remnants from the used boxes of the refills, so that in the event, a calculation of effective usage of the system could be made retrospectively.

**Results**

There were no drop outs in the study. None of the subjects suffered from irritation or allergic phenomena. In all treated patients, an improvement in skin condition could be observed.

**Keratosis**

In group A, the degree of keratosis decreased from an average value derived from the mean of the visual scale (Figure 3) of 3.31±0.54 at the initial examination to 2.59±0.61 at the second examination and to the value of 1.21±0.31 at the end of the observational period. Group B showed no change in the degree of keratosis. The corresponding keratosis values for the control group were 3.25±0.46 at the start of the study and 3.06±0.56 during the third examination at 2 months.

The improvement in keratosis can be clearly seen in Table 3 and Figure 4.

**General conditions of the skin**

Assessment of general conditions according to the arbitrary scale (Table 2) revealed improvement in the skin conditions of all members of group A, most of whom (more than 60%) displayed degree 4 or 5 improvement when compared to the basically stable conditions noted in the members of group B (Figure 5). Most patients treated with Difoprev® displayed a reduction in the degree of keratosis of the skin (90%, of whom 15% had marked improvement) when compared to patients who used the sock alone with no microcapsules (only 10%, with slight improvement).

All treated patients recorded a sensation of improvement and agreeability of the device, and no problems in complying with the request for daily usage and in regard to the refilling process. By way of exemplification, comparisons

---

**Figure 5** Percentage of those who displayed improvement, subdivided in degrees of the general state of the skin at the end of the treatment period.

**Figure 6** Hyperkeratotic lesion of the left heel.

*Note: Appearance of the skin (A) before treatment and (B) on termination of treatment with Difoprev® (LVM Technologies, Bologna, Italy) in a member of group A.*
infectious in nature. Alongside the above considerations, it may be noted that elderly persons tend to consume liquids less regularly and this potentially leads to dehydration which is particularly evident in the skin. The possibility of using a system which enables moisturization of the skin of the shin and foot by simple means such as socks endowed with the characteristics of the Difoprev® system may thus provide a convenient remedy for elderly patients who are otherwise forced to apply creams, oils, or ointments (which for the reasons mentioned above, rarely provide guarantees of continuity of treatment).

The simple daily action of putting on a routine accessory such as socks can provide a readily applicable solution to the problem of dryness of the skin and a tendency to hyperkeratosis, while also eliminating the risk of intercurrent diseases and the need for application of topical preparations. Constant release of the active principle contained in the microcapsules of the Difoprev® system throughout the day (the duration of each refill is about 36 hours) ensures hydration of the skin and concurrently makes for greater sock–skin contact comfort. Well hydrated skin is more elastic and resistant and can reduce the risks of skin disruption and therefore ulceration. Positively charged nanoemulsions, like the one which we used, are particularly effective because of the electrical attraction between the particles and the negatively charged structures of the skin. Moreover, the small size of the particles and large surface area of application may help maximize the interaction between the skin and the lipids coated with glycoproteins. It goes without saying that the results obtained in this study can only be considered preliminary, given the few patients sampled on the basis of a distinctly clinical approach. Further in depth study and validation are required. However, the data obtained point to a significant improvement in the skin of patients treated with the Difoprev® system (compared to patients who wore the sock without microcapsules). A reduction in keratosis and a distinct improvement in the appearance of the skin were noted in group A (compared to the group B patients in whom improvement was practically absent). These findings indicate that the efficacy noted is owing to the properties of the system. Prevention is crucial to avoid progression of the disease of the skin from the early stages in which only predisposing conditions are present. The charged socks have the potential to aid prevention. As already seen for the skin of diabetic patients, Difoprev® may readily contribute to preventing skin lesions and the associated derived discomfort also experienced by elderly patients. The system is active, safe, and enables improved conditions of the skin of elderly patients by enhancing hydration and elasticity.

**Notes:** Appearance of the skin (A) before treatment and (B) on termination of treatment with Difoprev® (LVM Technologies, Bologna, Italy). Particularly evident are the reduction in depth of the lesions and the realignment of the lines of the epidermis.

**Figure 7** Macro-detail of the same case as that illustrated in Figure 6.
Disclosure

The author reports no conflicts of interest in this work.

References


Dovepress

Journal of Vascular Diagnostics

Publish your work in this journal

Journal of Vascular Diagnostics is an international, peer-reviewed journal of diagnostics, focusing on non invasive vascular investigation methods involved in the evaluation of vascular diseases. The journal is committed to the rapid publication in the fields of vascular diseases. Original research, review, case reports, expert opinion and commentaries are all considered for publication. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.